Global Bone Morphogenetic Protein 麻豆原创 Report 2018-2029

Publication ID:

HJR06230018

Publication Date:

June 29, 2023

Pages:

143

Publisher:

HJResearch

Countries:

Global [1]

USD 3,200.00

Medical Devices [2]

Pharmaceutical Manufacturing [3]

Pharma & Healthcare [4]

Description:

Bone Morphogenetic Protein (BMP) is a type of protein that stimulates the growth and repair of bones and other tissues in the body. BMPs are naturally occurring proteins found in the human body, but they can also be manufactured in a laboratory and used in medical treatments. This protein plays a critical role in Spinal Fusion, Trauma, Reconstruction, Oral Maxillofacial surgeries to stimulate bone growth and aid in the healing process.

The global Bone Morphogenetic Protein market is projected to reach US$593.34 million by 2022, with a compound annual growth rate (CAGR) of 2.9%. This growth is driven by multiple factors, including an increase in the aging population, the rise in demand for minimally invasive surgeries, and the growing incidence of bone-related disorders such as osteoporosis.

The market is primarily driven by the demand for Spinal Fusion procedures, which account for the largest share of the Bone Morphogenetic Protein industry. The demand for this procedure is driven by an increasing number of patients suffering from degenerative spinal conditions such as degenerative disc disease, herniated discs, and spinal stenosis.

The major global manufacturers of BMP include Fidia, Medtronic, TRB Chemedica, Meda Pharma, Sanofi Genzyme, Depuy Synthes, Bioventus, Laboratoire Genevrier, Recordati, Stryker, RTI Biologics, Croma-Pharma, Zimmer Biomet. These companies focus on research and development to develop new products, improve existing technologies and expand market reach through collaborations and partnerships.

The BMP market faces challenges such as stringent regulatory requirements, high costs associated with production, limited reimbursement options, and adverse events related to the use of BMP. However, the emergence of advanced technologies such as 3D printing and stem cell therapy holds great promise for the growth and innovation of this industry.

In conclusion, the Bone Morphogenetic Protein industry plays a critical role in stimulating bone growth and aiding the healing process in patients, particularly in Spinal Fusion, Trauma, Reconstruction, Oral Maxillofacial surgeries. With a compound annual growth rate of 2.9% and major global manufacturers focusing on research and development, this industry is expected to experience continued growth and innovation in the coming years. However, market challenges such as regulatory requirements, safety concerns, and production costs must be addressed to ensure the sustainable growth of the BMP industry.

The SWOT analysis of the Bone Morphogenetic Protein industry is as follows:

Strengths:
Bone Morphogenetic Protein is a naturally occurring protein that stimulates bone growth, making it an effective treatment option for a variety of bone-related disorders.
The BMP industry has experienced significant growth and is projected to continue growing due to an increase in aging population and demand for minimally invasive surgeries.
The BMP market has a large potential customer base, including patients suffering from degenerative spinal conditions, trauma victims, and those requiring reconstruction or oral maxillofacial surgeries.
Major global manufacturers are investing in research and development to improve BMP technology and develop new products.

Weaknesses:
Production costs associated with manufacturing BMP can be high, which may limit market growth and restrict access for some patients.
Regulatory requirements for BMP can be stringent, which may slow down the approval process and affect market expansion.
Adverse events have been reported in association with BMP usage, which could lead to safety concerns and damage the reputation of BMP manufacturers.

Opportunities:
Advances in technology such as 3D printing and stem cell therapy could provide new opportunities for BMP industry growth and innovation.
Increasing investments in healthcare infrastructure in emerging economies can offer new markets for BMP manufacturers.
Growing awareness about the benefits of BMP treatment and the need for improved bone growth technologies can lead to increased demand for BMP products.
Partnerships and collaborations with healthcare providers and research institutions can promote the development of new applications for BMP.

Threats:
Intense competition among BMP manufacturers can lead to price pressure and lower profit margins.
Changes in government regulations and policies could impact the BMP market, affecting product development and sales.
Economic instability and fluctuation in currency exchange rates could affect the profitability of BMP manufacturers and limit market expansion.
Emergence of alternative treatments for bone-related disorders could reduce the demand for BMP products.

Key players in global Bone Morphogenetic Protein market include:
Fidia
Medtronic
TRB Chemedica
Meda Pharma
Sanofi Genzyme
Depuy Synthes
Bioventus
Laboratoire Genevrier
Recordati
Stryker
RTI Biologics
Croma-Pharma
Zimmer Biomet

麻豆原创 segmentation, by product types:
rhBMP-2
rhBMP-7

麻豆原创 segmentation, by applications:
Spinal Fusion
Trauma
Reconstruction
Oral Maxillofacial

Table Of Contents:

1 Industry Overview of Bone Morphogenetic Protein
1.1 Research Scope
1.2 麻豆原创 Segmentation by Types of Bone Morphogenetic Protein
1.3 麻豆原创 Segmentation by End Users of Bone Morphogenetic Protein
1.4 麻豆原创 Dynamics Analysis of Bone Morphogenetic Protein
1.4.1 麻豆原创 Drivers
1.4.2 麻豆原创 Challenges
1.4.3 麻豆原创 Opportunities
1.4.4 Porter鈥檚 Five Forces

2 Major Manufacturers Analysis of Bone Morphogenetic Protein Industry
2.1 Fidia
2.1.1 Company Overview
2.1.2 Main Products and Specifications
2.1.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.1.4 Contact Information
2.2 Medtronic
2.2.1 Company Overview
2.2.2 Main Products and Specifications
2.2.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.2.4 Contact Information
2.3 TRB Chemedica
2.3.1 Company Overview
2.3.2 Main Products and Specifications
2.3.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.3.4 Contact Information
2.4 Meda Pharma
2.4.1 Company Overview
2.4.2 Main Products and Specifications
2.4.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.4.4 Contact Information
2.5 Sanofi Genzyme
2.5.1 Company Overview
2.5.2 Main Products and Specifications
2.5.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.5.4 Contact Information
2.6 Depuy Synthes
2.6.1 Company Overview
2.6.2 Main Products and Specifications
2.6.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.6.4 Contact Information
2.7 Bioventus
2.7.1 Company Overview
2.7.2 Main Products and Specifications
2.7.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.7.4 Contact Information
2.8 Laboratoire Genevrier
2.8.1 Company Overview
2.8.2 Main Products and Specifications
2.8.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.8.4 Contact Information
2.9 Recordati
2.9.1 Company Overview
2.9.2 Main Products and Specifications
2.9.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.9.4 Contact Information
2.10 Stryker
2.10.1 Company Overview
2.10.2 Main Products and Specifications
2.10.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.10.4 Contact Information
2.11 RTI Biologics
2.11.1 Company Overview
2.11.2 Main Products and Specifications
2.11.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.11.4 Contact Information
2.12 Croma-Pharma
2.12.1 Company Overview
2.12.2 Main Products and Specifications
2.12.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.12.4 Contact Information
2.13 Zimmer Biomet
2.13.1 Company Overview
2.13.2 Main Products and Specifications
2.13.3 Bone Morphogenetic Protein Sales Volume, Revenue, Price and Gross Margin (2018-2023)
2.13.4 Contact Information

3 Global Bone Morphogenetic Protein 麻豆原创 Analysis by Regions, Manufacturers, Types and End Users
3.1 Global Sales Volume and Revenue of Bone Morphogenetic Protein by Regions (2018-2023)
3.2 Global Sales Volume and Revenue of Bone Morphogenetic Protein by Manufacturers (2018-2023)
3.3 Global Sales Volume and Revenue of Bone Morphogenetic Protein by Types (2018-2023)
3.4 Global Sales Volume and Revenue of Bone Morphogenetic Protein by End Users (2018-2023)
3.5 Selling Price Analysis of Bone Morphogenetic Protein by Regions, Manufacturers, Types and End Users in (2018-2023)

4 Northern America Bone Morphogenetic Protein 麻豆原创 Analysis by Countries, Types and End Users
4.1 Northern America Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Countries (2018-2023)
4.2 Northern America Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Types (2018-2023)
4.3 Northern America Bone Morphogenetic Protein Sales Volume and Revenue Analysis by End Users (2018-2023)
4.4 United States Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
4.5 Canada Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)

5 Europe Bone Morphogenetic Protein 麻豆原创 Analysis by Countries, Types and End Users
5.1 Europe Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Countries (2018-2023)
5.2 Europe Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Types (2018-2023)
5.3 Europe Bone Morphogenetic Protein Sales Volume and Revenue Analysis by End Users (2018-2023)
5.4 Germany Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
5.5 France Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
5.6 UK Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
5.7 Italy Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
5.8 Russia Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
5.9 Spain Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
5.10 Netherlands Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)

6 Asia Pacific Bone Morphogenetic Protein 麻豆原创 Analysis by Countries, Types and End Users
6.1 Asia Pacific Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Countries (2018-2023)
6.2 Asia Pacific Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Types (2018-2023)
6.3 Asia Pacific Bone Morphogenetic Protein Sales Volume and Revenue Analysis by End Users (2018-2023)
6.4 China Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
6.5 Japan Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
6.6 Korea Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
6.7 India Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
6.8 Australia Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
6.9 Indonesia Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
6.10 Vietnam Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)

7 Latin America Bone Morphogenetic Protein 麻豆原创 Analysis by Countries, Types and End Users
7.1 Latin America Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Countries (2018-2023)
7.2 Latin America Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Types (2018-2023)
7.3 Latin America Bone Morphogenetic Protein Sales Volume and Revenue Analysis by End Users (2018-2023)
7.4 Brazil Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
7.5 Mexico Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
7.6 Argentina Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
7.7 Colombia Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)

8 Middle East & Africa Bone Morphogenetic Protein 麻豆原创 Analysis by Countries, Types and End Users
8.1 Middle East & Africa Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Countries (2018-2023)
8.2 Middle East & Africa Bone Morphogenetic Protein Sales Volume and Revenue Analysis by Types (2018-2023)
8.3 Middle East & Africa Bone Morphogenetic Protein Sales Volume and Revenue Analysis by End Users (2018-2023)
8.4 Turkey Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
8.5 Saudi Arabia Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
8.6 South Africa Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)
8.7 Egypt Bone Morphogenetic Protein Sales Volume, Revenue, Import and Export Analysis (2018-2023)

9 麻豆原创ing Channel, Distributors and Traders Analysis
9.1 麻豆原创ing Channel
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Distributors and Traders

10 Global Bone Morphogenetic Protein 麻豆原创 Forecast by Regions, Countries, Manufacturers, Types and End Users
10.1 Global Sales Volume and Revenue Forecast of Bone Morphogenetic Protein by Regions (2024-2029)
10.2 Global Sales Volume and Revenue Forecast of Bone Morphogenetic Protein by Types (2024-2029)
10.3 Global Sales Volume and Revenue Forecast of Bone Morphogenetic Protein by End Users (2024-2029)
10.4 Global Revenue Forecast of Bone Morphogenetic Protein by Countries (2024-2029)
10.4.1 United States Revenue Forecast (2024-2029)
10.4.2 Canada Revenue Forecast (2024-2029)
10.4.3 Germany Revenue Forecast (2024-2029)
10.4.4 France Revenue Forecast (2024-2029)
10.4.5 UK Revenue Forecast (2024-2029)
10.4.6 Italy Revenue Forecast (2024-2029)
10.4.7 Russia Revenue Forecast (2024-2029)
10.4.8 Spain Revenue Forecast (2024-2029)
10.4.9 Netherlands Revenue Forecast (2024-2029)
10.4.10 China Revenue Forecast (2024-2029)
10.4.11 Japan Revenue Forecast (2024-2029)
10.4.12 Korea Revenue Forecast (2024-2029)
10.4.13 India Revenue Forecast (2024-2029)
10.4.14 Australia Revenue Forecast (2024-2029)
10.4.15 Indonesia Revenue Forecast (2024-2029)
10.4.16 Vietnam Revenue Forecast (2024-2029)
10.4.17 Brazil Revenue Forecast (2024-2029)
10.4.18 Mexico Revenue Forecast (2024-2029)
10.4.19 Argentina Revenue Forecast (2024-2029)
10.4.20 Colombia Revenue Forecast (2024-2029)
10.4.21 Turkey Revenue Forecast (2024-2029)
10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
10.4.23 South Africa Revenue Forecast (2024-2029)
10.4.24 Egypt Revenue Forecast (2024-2029)

11 Industry Chain Analysis of Bone Morphogenetic Protein
11.1 Upstream Major Raw Materials and Equipment Suppliers Analysis of Bone Morphogenetic Protein
11.1.1 Major Raw Materials Suppliers with Contact Information Analysis of Bone Morphogenetic Protein
11.1.2 Major Equipment Suppliers with Contact Information Analysis of Bone Morphogenetic Protein
11.2 Downstream Major Consumers Analysis of Bone Morphogenetic Protein
11.3 Major Suppliers of Bone Morphogenetic Protein with Contact Information
11.4 Supply Chain Relationship Analysis of Bone Morphogenetic Protein

12 Bone Morphogenetic Protein New Project Investment Feasibility Analysis
12.1 Bone Morphogenetic Protein New Project SWOT Analysis
12.2 Bone Morphogenetic Protein New Project Investment Feasibility Analysis
12.2.1 Project Name
12.2.2 Investment Budget
12.2.3 Project Product Solutions
12.2.4 Project Schedule

13 Bone Morphogenetic Protein Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.2 References and Data Sources
14.2.1 Primary Sources
14.2.2 Secondary Paid Sources
14.2.3 Secondary Public Sources
14.3 Abbreviations and Units of Measurement
14.4 Author Details
14.5 Disclaimer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.